Biotechnology news

• Biomarker Screen Improves Accuracy of Chemical Genotoxicity Testing

  05-12-2017 16:31
  An international research team has developed an in vitro  transcriptomic biomarker that can predict, with up to 90% accuracy, whether a drug candidate or other chemical compound is likely to cause the type of cellular injury that can lead to cancer. The TGx-DDI biomarker comprises a panel of 64 transcribed genes that reflect cellular stress response due to DNA damage. And unlike current genotoxicity assays, which demonstrate high rates of false-positive results for cancer risk, the TGx-DDI
  
  Read more

• “Resolvin” Cancer Cell Debris: Clearing Every Litter Bit Improves Therapy

  05-12-2017 16:30
  Conventional cancer therapy can generate a dangerous mess—dying, dead, and disintegrating cancer cells. As the cancer cell debris piles up, it worsens the tumor microenvironment, which becomes proinflammatory and even starts promoting tumor growth. The debris, however, needn’t be left to accumulate like so much roadside trash. It can be cleared away by resolvins, molecules that occur naturally in the body and are currently entering clinical development.Tidying up the debris-strewn tu
  
  Read more

• Old Antibiotic Repurposed to Treat TB

  05-12-2017 16:16
  Tuberculosis (TB) remains a global public health threat and a leading cause of death worldwide, therefore finding new drugs to effectively control and treat the disease is paramount. Now, new research from scientists at the University of Warwick and The Francis Crick Institute could help tackle TB and other life-threatening microbial diseases more effectively, thanks to an old antibiotic. Findings from the new study—published today in Nature Communications in an article entitled “ In
  
  Read more

• Opioid Decline Sparks Depomed Job and HQ Cuts, Up to $540M Commercialization Deal with Collegium

  05-12-2017 15:49
  Depomed said it will cut about three-quarters of its sales force and 40% of its headquarters staff following a planned relocation next year, as it adopts a new business model away from reliance on opioid pain drugs—reflected by an up-to-$540 million-plus commercialization deal disclosed yesterday.Depomed has granted commercialization rights to its top selling products—the Nucynta ® (tapentadol) opioid franchise, including its extended-release and immediate-release forms—to
  
  Read more

• Advertisement

• Voting Opens for BIO CEO and Investor Conference “Buzz of BIO” Contest

  05-12-2017 15:00
  Finalists in each of three categories have been named in this year’s Buzz of BIO contest at the 2018 BIO CEO & Investor Conference.
  Meet this year’s nominees and vote for your favorite innovative biotech companies in the “Public Therapeutic Biotech”, “Private Therapeutic Biotech”, and “Diagnostics and Beyond” categories. A Buzz of BIO winner in each category will receive a complimentary BIO CEO & Investor Conference conference registra
  
  Read more

• Novel Drug Shows Promising Results in Alzheimer’s Model

  05-12-2017 14:08
  Scientists report that a novel small-molecule drug, which works by stopping toxic ion flow in the brain that is known to trigger neuronal apoptosis, can restore brain function and memory in a mouse model of Alzheimer's disease (AD). The team believes the drug could be used to treat AD and other neurodegenerative diseases such as Parkinson's and amyotropic lateral sclerosis (ALS)."This is the first drug molecule that can regulate memory loss by directly blocking ions from leaking throug
  
  Read more

• CSL and Vitaeris Announce Strategic Partnership with Option to Acquire

  05-12-2017 03:28
  thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) and Vitaeris Inc. (Vitaeris) today announced that they have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection. 
  
  Read more

• CSL Confirms Phase 3 Clinical Trial of New Therapy for Heart Attack Survivors

  05-12-2017 01:57
  thumbnail Global biotherapeutics leaderCSL (ASX:CSL) today announced that it will proceed with a Phase 3 clinical trial for CSL112, the company’s novel therapy for reduction of early recurrent cardiovascular events in heart attack survivors. The decision has been made subject to final agreement with the US Food and Drug Administration (FDA) on important elements of the study design. 
  
  Read more

• Advertisement

Follow @Biotech_News_AU on Twitter!